Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Disposition and Metabolism of [14C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites

Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, Michiyuki Suzuki, Carsten T. Beuckmann, Takaaki Kameyama, Shoji Asakura and Kazutomi Kusano
Drug Metabolism and Disposition January 2021, 49 (1) 31-38; DOI: https://doi.org/10.1124/dmd.120.000229
Takashi Ueno
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Takashi Ueno
Tomomi Ishida
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jagadeesh Aluri
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michiyuki Suzuki
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten T. Beuckmann
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaaki Kameyama
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoji Asakura
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazutomi Kusano
Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 49 no. 1 31-38
DOI 
https://doi.org/10.1124/dmd.120.000229
PubMed 
33144331

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received August 28, 2020
  • Accepted October 26, 2020
  • Published online December 10, 2020.

Article Versions

  • Earlier version (November 3, 2020 - 17:26).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Takashi Ueno,
  2. Tomomi Ishida,
  3. Jagadeesh Aluri,
  4. Michiyuki Suzuki,
  5. Carsten T. Beuckmann,
  6. Takaaki Kameyama,
  7. Shoji Asakura, and
  8. Kazutomi Kusano
  1. Eisai Co., Ltd., Ibaraki, Japan (T.U., T.I., C.T.B., T.K., S.A., K.K.); Eisai Inc., Woodcliff Lake, New Jersey (J.A.); and EA Pharma Co., Ltd., Tokyo, Japan (M.S.)
  1. Address correspondence to:
    Takashi Ueno, Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan. E-mail: t3-ueno{at}hhc.eisai.co.jp
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: November 2020 to May 2023

AbstractFullPdf
Nov 202047935332
Dec 202035077109
Jan 202127424185
Feb 20211662625
Mar 2021732426
Apr 20211122119
May 202186721
Jun 2021901114
Jul 20211031023
Aug 2021881011
Sep 202178939
Oct 202173530
Nov 20211581741
Dec 2021352138
Jan 2022134141
Feb 202255255
Mar 202255036
Apr 2022114949
May 202234137
Jun 202284840
Jul 202264658
Aug 202294035
Sep 2022113928
Oct 2022184048
Nov 2022124887
Dec 202295038
Jan 202352631
Feb 202394736
Mar 202373730
Apr 202342740
May 202364026

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (1)
Drug Metabolism and Disposition
Vol. 49, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disposition and Metabolism of [14C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

ADME Properties of Lemborexant in Humans

Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, Michiyuki Suzuki, Carsten T. Beuckmann, Takaaki Kameyama, Shoji Asakura and Kazutomi Kusano
Drug Metabolism and Disposition January 1, 2021, 49 (1) 31-38; DOI: https://doi.org/10.1124/dmd.120.000229

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

ADME Properties of Lemborexant in Humans

Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, Michiyuki Suzuki, Carsten T. Beuckmann, Takaaki Kameyama, Shoji Asakura and Kazutomi Kusano
Drug Metabolism and Disposition January 1, 2021, 49 (1) 31-38; DOI: https://doi.org/10.1124/dmd.120.000229
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sex- and lifestyle-related factors affect hepatic CYP levels
  • Adipocyte PXR does not play an essential role in obesity.
  • CYP3A-mediated oxidation of DABE and BIBR0951
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics